Xi Chen Lin
Vermögen: 3 Mio $ am 31.05.2026
Vermögen: 3 Mio $ am 31.05.2026
Dr. Xi Chen Lin is a Chief Scientific Officer & GM-Structure Shanghai at Structure Therapeutics, Inc. and a General Manager at Shanghai ShouTi Biotechnology Co. Ltd. Dr. Lin was previously employed as a Head-Asia Pacific External Innovation by Novo Nordisk A/S.
He received his undergraduate degree from Peking University and a doctorate degree from The Pennsylvania State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.06.2026 | 228.960 ( 0,16 % ) | 3 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2019 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.07.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Structure Therapeutics, Inc.
Structure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops molecule therapeutics to treat chronic diseases | Health Technology |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen